莫德納在最新研發更新中展示人工智慧與 mRNA 技術
Moderna showcases AI and mRNA tech in latest R&D update
Updated at: June 25, 2026 at 06:00 AM
莫德納正在重新定位為一家數位優先的生技公司，利用人工智慧來重塑 mRNA 藥物開發的領域。
Moderna is redefining itself as a digital-first biotech company, leveraging artificial intelligence to transform the landscape of mRNA drug development.
透過將 mRNA 視為「生命的軟體」，莫德納使用人工智慧以史無前例的速度優化疫苗的設計與製造。
By treating mRNA as the 'software of life,' Moderna uses AI to optimize the design and manufacturing of vaccines at unprecedented speeds.
藉由與 OpenAI 的策略合作，該公司已將客製化的人工智慧工具整合至營運的各個層面，從法務部門到複雜的研究分析皆涵蓋其中。
Through a strategic partnership with OpenAI, the company has integrated custom AI tools across its operations, from legal departments to complex research analytics.
為支持此願景，莫德納與卡內基美隆大學合作成立人工智慧學院，以確保其員工始終保持在技術創新的最前線。
To support this vision, Moderna launched an AI Academy with Carnegie Mellon University to ensure its workforce remains at the cutting edge of technological innovation.
除了技術層面，莫德納也正成功擴大其醫療產品線。
Beyond technology, Moderna is successfully expanding its medical pipeline.
近期的重大突破包括其流感疫苗獲得美國食品藥物管理局（FDA）諮詢委員會的正面投票，以及其個人化黑色素瘤癌症疫苗令人振奮的五年存活數據。
Recent breakthroughs include a positive FDA advisory committee vote for its influenza vaccine and promising five-year survival data for its personalized melanoma cancer vaccine.
藉由將這些先進的計算能力與多樣化的臨床計畫相結合，莫德納正證明其平台技術的應用遠超乎最初的成功，使該公司在下一代全球醫學領域中佔據領導地位。
By combining these advanced computational capabilities with a diverse range of clinical programs, Moderna is proving that its platform technology can extend far beyond its initial success, positioning the company as a leader in the next generation of global medicine.
